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ABSTRACT  
We describe a 66-year-old man who developed bilateral choroidal detachment that was induced by 
unilateral topical administration of a fixed combination of 1% brinzolamide and 0.5% timolol maleate the 
day after an uneventful phacoemulsification surgery and intraocular lens implantation involving his right 
eye. We believe that the reaction was an idiosyncratic reaction, most likely against brinzolamide. The 
condition improved rapidly after the cessation of the fixed combination of brinzolamide and timolol 
maleate and treatment with 1% topical prednisolone acetate every hour and 1% cyclopentolate twice a day 
bilaterally. Although there are several similar cases involving choroidal detachment after oral 
acetazolamide and topical dorzolamide treatment mentioned in the literature, the present case is the first 
case report involving bilateral choroidal detachment after topical treatment with brinzolamide.  
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INTRODUCTION 
        Choroidal detachment (involving ciliochoroidal 
detachment, uveal effusion, or ciliochoroidal effusion) is 
characterized by the accumulation of abnormal fluid in 
the suprachoroidal space (1-2). There are several case 
reports describing ciliochoroidal effusion (occasionally 
with acute angle-closure glaucoma) following treatment 
with oral acetazolamide or topical dorzolamide (3-8). 
However, this is the first case report on bilateral 
choroidal detachment after topical treatment with 
brinzolamide, a carbonic anhydrase inhibitor derived 
from a novel class of heterocyclic sulfonamides with high 
affinity and inhibitory activity against human carbonic 
anhydrase II (9) 
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CASE REPORT 
   A 66-year-old man was referred to us for the treatment 
of bilateral choroidal detachment following an 
uneventful unilateral phacoemulsification surgery and 
intraocular lens (IOL) implantation in his right eye. His 
right eye was treated with a fixed combination of topical 
0.5% timolol maleate and 1% brinzolamide twice a day 
and 1% prednisolone acetate six times a day, beginning 
the morning after the surgery. He started to experience 
visual deterioration first in the right eye than in the left 
eye later on the same day.  
An examination on the fourth day after the surgery 
showed that the patient’s visual acuity was 4/10 in in the 
right eye (-1.0 x 90) and 7/10 in the left eye (+0.75). A 
slit-lamp examination revealed mild ciliary injection and a 
slightly shallow anterior chamber in both eyes. In the 
right eye, there were a moderate number of cells in the 
anterior chamber (grade 2+) and the IOL was well-
centered in the bag, while the left eye had grade 2+ 
nuclear sclerosis. The intraocular pressure (assessed 
using an applanation tonometer) was 10 mmHg in the 
right eye and 20 mmHg in the left eye. A dilated fundus 
examination revealed bilateral 360° annular choroidal 
detachment, which was more pronounced in the right 
eye (i.e., the eye that was operated on) (Figure 1). No 
pertinent past medical history was presented relevant to 
the formation of the bilateral choroidal detachment. The 
choroidal detachment in the left eye was detected using 
a Goldmann three-mirror lens. Optical coherence 
tomography (OCT) images indicated that both maculae 
were normal. The axial lengths were 23.12 and 23.09 mm 
in the right and left eye, respectively, as assessed using 
an IOL Master 500 (software version 2.02, Carl Zeiss, 
Jena, Germany). The anterior chamber depth was 3.12 
mm in the right eye and 2.51 mm in the left eye, based 
on anterior segment OCT (Visante OCT system, Model 
1000, software version 3.0, Carl Zeiss AG) (Figure 2).  
  
Figure 1: Color photograph of the right eye, obtained four days 
after the unilateral phacoemulsification surgery and IOL 
implantation, showing extensive choroidal detachment. 
 
  
Figure 2: Anterior segment optical coherence tomography 
image showing the anterior chamber depth in the right and left 
eyes at initial presentation. 
 
We believe that the bilateral choroidal detachment was 
most likely an idiosyncratic reaction to the brinzolamide. 
The fixed combination of brinzolamide and timolol 
maleate was discontinued, and 1% prednisolone acetate 
was administered bilaterally every hour, while 1% 
cyclopentolate was administered bilaterally twice a day.  
Three days after treatment with fixed combination of 
brinzolamide and timolol maleate was discontinued, the 
patient’s visual acuity was 20/25 in the right eye and 
20/20 in the left eye. The intraocular pressure was 16 
mmHg in the right eye and 17 mmHg in the left eye. A 
fundus examination revealed that the choroidal 
detachment had markedly improved in the right eye 
(Figure 3) and almost totally cleared in the left eye. The 
anterior chamber depth had increased to 3.39 mm in the 
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right eye and 3.00 mm in the left eye (as assessed using 
the Visante OCT system) (Figure 4). 
 
 
Figure 3: Color photograph of the right eye, obtained 3 days 
after the discontinuation of the fixed combination of 0.5% 
timolol maleate and 1% dorzolamide, showing marked 
resolution of the original choroidal detachment. 
  
 
Figure 4: Anterior segment optical coherence tomography 
images, 3 days after the discontinuation of the fixed 
combination of 0.5% timolol maleate and 1% dorzolamide, 
showing increased anterior chamber depth in the right and left 
eyes. 
 
DISCUSSION 
  It is known that oral acetazolamide and topical 
dorzolamide can cause ciliary body swelling, choroidal 
effusion, and forward displacement of the iris–lens 
diaphragm, most likely due to idiosyncratic reactions. 
Krieg and Schipper (10) suggested that the sulfonamide 
group of acetazolamide and dorzolamide stimulates the 
synthesis of prostaglandin E2, which in turn causes 
vasodilatation and increased vascular permeability in the 
anterior uvea.  
Several case reports have indicated that there is a causal 
relationship between oral acetazolamide and choroidal 
detachment. Mancino et al. (4) reported on a 76-year-old 
man who underwent cataract extraction and IOL 
implantation and developed bilateral angle-closure 
glaucoma with extensive choroidal detachment following 
the intake of two 250-mg doses of oral acetazolamide 
(the first was taken immediately after the surgery and 
the second was taken the next day). Interestingly, the 
same surgery was uneventfully performed on the 
patient’s other eye 7 years earlier. Cessation of 
acetazolamide and treatment with high-dose intravenous 
steroid therapy resulted in rapid clinical improvement. 
Malagola et al. (5) reported on a 71-year-old man who 
underwent routine unilateral cataract surgery and IOL 
implantation (the patient’s other eye was phakic). The 
patient took 250 mg oral acetazolamide 4 hours after the 
surgery and, 3 hours later, he experienced severe pain 
and bilateral visual deterioration. Both anterior 
chambers were shallow and the intraocular pressure was 
>50 mm Hg in both eyes. B-scan ultrasonography showed 
bilateral choroidal effusion. The patient discontinued the 
acetazolamide and, 3 days later, the intraocular pressure 
returned to normal and the myopic shift decreased. A 
month later, the patient underwent cataract surgery on 
the other eye without use of a sulfonamide medication, 
and no complications were noted. Parthasarathi et al. (5) 
reported on a 66-year-old man with chronic open-angle 
glaucoma who underwent unilateral cataract surgery 
with IOL implantation. He was treated with 250 mg oral 
acetazolamide immediately after the surgery and 
overnight. Three hours after the surgery, the patient 
developed bilateral angle-closure glaucoma and 
choroidal effusion. The condition resolved only after the 
acetazolamide was discontinued. 
Like oral acetazolamide, topical dorzolamide may also 
induce choroidal detachment. Davani et al. (6) reported 
on a 70-year-old woman with ocular hypertension who 
had undergone bilateral extracapsular cataract extraction 
and posterior chamber IOL implantation 20 years 
previously. She was originally being treated with topical 
0.05% timolol maleate but switched to a fixed 
combination of topical 0.5% timolol maleate and 1% 
dorzolamide. Five days after switching, she experienced 
bilateral visual deterioration and bilateral choroidal 
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detachment. However, a further five days after cessation 
of the fixed combination of timolol maleate and 
dorzolamide, the choroidal detachment subsided in both 
eyes and treatment with 0.5% timolol maleate was re-
initiated without any fundus changes. Goldberg et al. (7) 
reported a case of a 76-year-old patient with open-angle 
glaucoma and no history of previous ocular surgery who 
developed unilateral choroidal detachment a day after 
initiating treatment with 1% topical dorzolamide and 
0.5% timolol maleate twice a day. Both drugs were 
discontinued and corticosteroid drops were 
administered, and the choroidal detachment resolved a 
week later. Doherty et al. (8) reported on a 75-year-old 
man who had undergone an uncomplicated 
phacoemulsification surgery with IOL implantation 7 
years previously, and who had been using a fixed 
combination of latanoprost and timolol maleate for a 
long time for the treatment of chronic open-angle 
glaucoma. This regimen was supplemented with 
dorzolamide drops and, two days later, the patient’s 
visual acuity declined in both eyes. Fundoscopy revealed 
severe bilateral choroidal detachment without significant 
anterior chamber shallowing. The choroidal detachment 
resolved completely 2 weeks after the cessation of the 
topical dorzolamide. 
Our case is the only reported case characterized by 
choroidal detachment and a slightly shallow anterior 
chamber in both eyes that is related to an idiosyncratic 
reaction to brinzolamide. Initiation and cessation of the 
drug showed a temporal relationship with the bilateral 
onset and resolution of the effusion, respectively. We 
recommend that clinicians consider topical brinzolamide 
(in addition to topical dorzolamide and oral 
acetazolamide) as a potential causative agent if choroidal 
detachment (particularly bilateral detachment) is 
detected after the administration of these drugs. 
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